Detalles de la búsqueda
1.
Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients.
J Transl Med
; 19(1): 372, 2021 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34461927
2.
Synergism between the phosphatidylinositol 3-kinase p110ß isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation.
Cancer Cell Int
; 21(1): 24, 2021 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33407478
3.
Correction to: Synergism between the phosphatidylinositol 3-kinase p110ß isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation.
Cancer Cell Int
; 21(1): 403, 2021 Jul 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34321007
4.
Nuclear transport of phosphorylated LanCL2 promotes invadopodia formation and tumor progression of glioblastoma by activating STAT3/Cortactin signaling.
J Adv Res
; 2024 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38492734
5.
A Multi-targeted Natural Flavonoid Myricetin Suppresses Lamellipodia and Focal Adhesions Formation and Impedes Glioblastoma Cell Invasiveness and Abnormal Motility.
CNS Neurol Disord Drug Targets
; 17(7): 557-567, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29886836
6.
Effect of ribozyme against transforming growth factorbeta1 on biological character of activated HSCs.
IUBMB Life
; 57(1): 31-9, 2005 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-16036560
Resultados
1 -
6
de 6
1
Próxima >
>>